Immunome (NASDAQ:IMNM) Director Sells $301,058.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 11,048 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $27.25, for a total value of $301,058.00. Following the sale, the director owned 92,211 shares in the company, valued at $2,512,749.75. The trade was a 10.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Tuesday, August 11th, Isaac Barchas sold 62,291 shares of Immunome stock. The stock was sold at an average price of $26.23, for a total value of $1,633,892.93.
• On Monday, August 10th, Isaac Barchas sold 10,125 shares of Immunome stock. The stock was sold at an average price of $26.07, for a total transaction of $263,958.75.
• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total transaction of $397,362.88.
• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total transaction of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The shares were sold at an average price of $24.20, for a total transaction of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The stock was sold at an average price of $24.11, for a total transaction of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total value of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The shares were sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Trading Up 3.0%

NASDAQ:IMNM opened at $27.20 on Friday. The stock has a 50 day moving average of $22.20 and a 200-day moving average of $22.24. The firm has a market capitalization of $3.09 billion, a PE ratio of -10.75 and a beta of 2.08. Immunome, Inc. has a 52 week low of $8.66 and a 52 week high of $28.62.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.14). As a group, analysts predict that Immunome, Inc. will post -2.3 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on IMNM. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Wedbush upped their price target on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday. Barclays began coverage on shares of Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective on the stock. HC Wainwright reiterated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Finally, Citigroup reissued a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.64.

Trending Headlines about Immunome

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Investors remain focused on the FDA’s acceptance of Immunome’s varegacestat NDA and an April 2027 PDUFA decision date. The company also expects initial 2026 data from its Phase 1 IM-1021 ROR1 antibody-drug conjugate program, providing potential catalysts for the stock. Immunome catalysts and Strong Buy analysis
• Positive Sentiment: HC Wainwright maintained a Buy rating and projects a potential transition to profitability over the longer term, forecasting positive EPS of $0.40 in fiscal 2029 and $1.08 in fiscal 2030. These estimates support the longer-term investment case despite current losses.
• Neutral Sentiment: Director Isaac Barchas sold shares under a pre-arranged Rule 10b5-1 plan, including 98,712 shares from August 10–12 for roughly $2.6 million. The planned nature of the transactions makes them a less definitive signal about management’s current outlook, although the sales may weigh on sentiment. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the consensus loss of $0.51. The earnings miss triggered a recent gap lower and highlights continued cash-burn and execution risks for the clinical-stage biotechnology company. Immunome shares gap down after earnings miss
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for the near and medium term: Q3 2026 to $(0.65) from $(0.51), Q4 to $(0.68) from $(0.53), fiscal 2026 to $(2.45) from $(1.99), and fiscal 2027 to $(2.11) from $(1.72). The cuts suggest slower progress toward profitability, even though the firm retained its Buy rating.

Hedge Funds Weigh In On Immunome

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Planning raised its position in shares of Immunome by 4.0% during the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after buying an additional 710 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Immunome by 14.4% in the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock valued at $159,000 after acquiring an additional 935 shares in the last quarter. Allworth Financial LP acquired a new position in shares of Immunome during the second quarter valued at approximately $25,000. California State Teachers Retirement System raised its holdings in Immunome by 1.8% during the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock worth $1,439,000 after purchasing an additional 1,167 shares in the last quarter. Finally, Assetmark Inc. lifted its position in Immunome by 46.6% in the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after purchasing an additional 1,442 shares during the period. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.